Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Intact p73 function is shown to be an important determinant of cellular sensitivity to anticancer agents. Inhibition of p73 function by dominant-negative proteins or by mutant p53 abrogates apoptosis and cytotoxicity induced by these agents. A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers. Clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is influenced by this polymorphism, cancers expressing 72R mutants having lower response rates than those expressing 72P mutants. Polymorphism in p53 may influence individual responsiveness to cancer therapy.


Journal article


Cancer Cell

Publication Date





387 - 402


Adult, Aged, Apoptosis, Carcinoma, Squamous Cell, DNA-Binding Proteins, Drug Resistance, Neoplasm, Drug Therapy, Female, Genes, Tumor Suppressor, Genes, p53, Head and Neck Neoplasms, Humans, Immunoblotting, Immunohistochemistry, Male, Middle Aged, Mutation, Nuclear Proteins, Plasmids, Polymorphism, Single Nucleotide, Prognosis, RNA, Small Interfering, Tumor Cells, Cultured, Tumor Protein p73, Tumor Suppressor Proteins